New shot aims to prevent dangerous clots in High-Risk patients
Disease control
Recruiting now
This early-stage study tests a single injection of CITY-FXI, a drug designed to lower clotting risk by targeting a protein called Factor XI. It includes healthy adults and those with Factor V Leiden or prothrombin G20210A mutations, which increase clot risk. The main goal is to c…
Phase: PHASE1 • Sponsor: City Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 09:08 UTC